Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.

Alzheimer's research & therapy·2015
Same author

Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study.

Diving and hyperbaric medicine·2015
Same author

Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair.

Neurochemistry international·2015
Same author

Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases.

Neurobiology of aging·2015
Same author

Neuromodulation of fast-spiking and non-fast-spiking hippocampal CA1 interneurons by human cerebrospinal fluid.

The Journal of physiology·2015
Same author

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Molecular neurodegeneration·2015

Video Experimental Relacionado

Updated: Jul 6, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

La enfermedad de Alzheimer es la enfermedad de Alzheimer.

Kaj Blennow1, Mony J de Leon, Henrik Zetterberg

  • 1Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren's University Hospital, Mölndal, Sweden. kaj.blennow@neuro.gu.se

Lancet (London, England)
|August 1, 2006
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Alzheimer, una demencia común, involucra placas beta amiloide y enredos tau. Sus causas complejas, especialmente en formas esporádicas, involucran el envejecimiento, la genética y los factores ambientales, lo que requiere más investigación para tratamientos efectivos.

Más Videos Relacionados

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 6, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Área de la Ciencia:

  • Neurología Neurología.
  • Biología Molecular Biología Molecular
  • Genética La genética.

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) es la principal causa de demencia.
  • Las principales características patológicas incluyen placas de beta amiloide (Abeta) y ovillos de tau hiperfosforilados.
  • La comprensión de la patogénesis de la EA está avanzando, revelando una complejidad significativa.

Objetivo del estudio:

  • Revisar la epidemiología, genética, patogénesis, diagnóstico y tratamiento de la enfermedad de Alzheimer.
  • Para resaltar los desarrollos recientes y las controversias en curso en la investigación de la EA.
  • Para diferenciar entre las formas familiares y esporádicas de la enfermedad de Alzheimer.

Principales métodos:

  • Revisión de la literatura existente sobre la enfermedad de Alzheimer.
  • Análisis de la patogénesis molecular, incluyendo Abeta y tau.
  • Examen de los factores de riesgo genéticos y ambientales para el Alzheimer esporádico.

Principales resultados:

  • La EA familiar es rara, de inicio temprano y está relacionada con las mutaciones del gen APP y de la presenilina que afectan el metabolismo de Abeta.
  • La EA esporádica es común, con una etiología desconocida atribuida al envejecimiento, las interacciones genéticas y ambientales.
  • La heterogeneidad de la EA esporádica complica la comprensión y el desarrollo de tratamientos.

Conclusiones:

  • La patogénesis de la enfermedad de Alzheimer es compleja, ya que involucra factores genéticos y ambientales.
  • La investigación adicional es crucial para desentrañar las causas de la enfermedad de Alzheimer esporádica y desarrollar terapias dirigidas.
  • Una comprensión completa de la enfermedad de Alzheimer, desde los mecanismos moleculares hasta los factores de riesgo, es esencial para el progreso clínico.